1-8 January 2016
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
Laquinimod study concerns
The higher doses of laquinimod have been dropped from two trails - one in relapsing remitting MS, the other in primary progressive MS - over concerns about heart related side effects. The trials are continuing with a smaller dose of laquinimod being compared to placebo
MS Trust link: Laquinimod - drugs in development